Jeffrey Lawson
Fondateur chez InnAVasc Medical, Inc.
Postes actifs de Jeffrey Lawson
Sociétés | Poste | Début | Fin |
---|---|---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | 01/07/2018 | - |
Corporate Officer/Principal | 20/11/2020 | - | |
Directeur Général | 01/06/2018 | 20/11/2020 | |
Directeur Technique/Scientifique/R&D | 01/01/2015 | - | |
President | 01/01/2018 | 20/11/2020 | |
InnAVasc Medical, Inc.
InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Directeur/Membre du Conseil | 13/05/2013 | - |
Fondateur | 13/05/2013 | - | |
Kidney Health Initiative | Directeur/Membre du Conseil | - | - |
Vascular Access Society of The Americas | Directeur/Membre du Conseil | - | - |
Foundation For Women & Girls With Blood Disorders | Directeur/Membre du Conseil | - | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Directeur Général | 12/10/2023 | - |
Historique de carrière de Jeffrey Lawson
Anciens postes connus de Jeffrey Lawson
Sociétés | Poste | Début | Fin |
---|---|---|---|
HUMACYTE, INC. | Directeur/Membre du Conseil | 26/08/2021 | 31/12/2021 |
Corporate Officer/Principal | 26/08/2021 | 31/12/2021 |
Formation de Jeffrey Lawson
University of Vermont College of Medicine | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Pays-Bas | 2 |
Opérationnelle
Director/Board Member | 6 |
Chief Executive Officer | 2 |
Corporate Officer/Principal | 2 |
Sectorielle
Health Technology | 5 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
HUMACYTE, INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
Vascular Access Society of The Americas | |
InnAVasc Medical, Inc.
InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Health Technology |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
Kidney Health Initiative | |
Foundation For Women & Girls With Blood Disorders |
- Bourse
- Insiders
- Jeffrey Lawson
- Expérience